|
FDA Lacks Policy to Deal With EU Falsified Medicines Directive, Shortage Concern Looms
The FDA’s lack of a policy or guidance to help API manufacturers deal with a new European directive is causing concern among manufacturers about lost sales and drug shortages in Europe, an expert says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
|
Subscribe
Archives